Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-blind, Sham-procedure Controlled Study to Assess the Safety and Tolerability and Explore the Efficacy of ISIS 396443 (BIIB058) Administered Intrathecally in Subjects With Spinal Muscular Atrophy Who Are Not Eligible to Participate in the Clinical Studies ISIS 396443-CS3B or ISIS 396443-CS4
Conditions
Interventions
Nusinersen
Sham Procedure
Locations
7
United States
David Geffen School of Medicine at UCLA
Los Angeles, California, United States
Connecticut Childrens Medical
Hartford, Connecticut, United States
The Johns Hopkins Hospital
Baltimore, Maryland, United States
Gillette Children's Specialty Healthcare
Saint Paul, Minnesota, United States
The University of Texas Southwestern Medical Center
Dallas, Texas, United States
Seattle Children's Research Institute
Seattle, Washington, United States
Start Date
August 19, 2015
Primary Completion Date
September 24, 2018
Completion Date
September 24, 2018
Last Updated
February 17, 2021
NCT05866419
NCT06839469
NCT06955897
NCT06321965
NCT07223489
NCT07332702
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions